• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肝硬化中的肝性脑病]

[Hepatic encephalopathy in liver cirrhosis].

作者信息

Labenz Christian

出版信息

Dtsch Med Wochenschr. 2026 Feb;151(4):149-155. doi: 10.1055/a-2647-5748. Epub 2026 Feb 9.

DOI:10.1055/a-2647-5748
PMID:41662861
Abstract

Hepatic encephalopathy (HE) is a common and serious complication of liver cirrhosis, associated with significant morbidity and mortality. Pathophysiologically, it results from a complex interplay of hyperammonemia, systemic inflammation, neuroinflammatory processes, and microbial dysbiosis. Clinically, HE ranges from subtle cognitive impairments (minimal HE) to coma (grade 4 HE). Diagnosis requires thorough clinical assessment and the use of specialized testing methods, particularly to detect subclinical alterations. In everyday practice, ammonia levels have limited diagnostic value but may be useful for differential diagnosis. The acute treatment of overt hepatic encephalopathy (OHE) is primarily based on the administration of lactulose, optionally supplemented with intravenous L-ornithine-L-aspartate. For secondary prophylaxis lactulose is the treatment of choice and in patients with recurrent episodes, the combination of rifaximin and lactulose is well established. Nutritional recommendations are a key component of therapy, especially to prevent sarcopenia. In cases of refractory HE or recurrent relapses despite guideline-based treatment, liver transplantation should always be considered. In general, early detection and individualized management of HE is essential to preserve and improve quality of life, prognosis, and functional independence of the affected patients.

摘要

肝性脑病(HE)是肝硬化常见且严重的并发症,具有较高的发病率和死亡率。在病理生理学上,它是由高氨血症、全身炎症、神经炎症过程和微生物群落失调的复杂相互作用导致的。临床上,HE的表现从轻微的认知障碍(轻微肝性脑病)到昏迷(4级肝性脑病)不等。诊断需要全面的临床评估并使用专门的检测方法,特别是用于检测亚临床改变。在日常实践中,氨水平的诊断价值有限,但可能有助于鉴别诊断。显性肝性脑病(OHE)的急性治疗主要基于乳果糖的给药,可选择静脉注射L-鸟氨酸-L-天冬氨酸作为补充。对于二级预防,乳果糖是首选治疗方法,对于复发患者,利福昔明和乳果糖联合使用已得到充分证实。营养建议是治疗的关键组成部分,尤其是预防肌肉减少症。对于难治性HE或尽管进行了基于指南的治疗仍反复复发的病例,应始终考虑肝移植。总体而言,早期发现和个体化管理HE对于维持和改善受影响患者的生活质量、预后和功能独立性至关重要。

相似文献

1
[Hepatic encephalopathy in liver cirrhosis].[肝硬化中的肝性脑病]
Dtsch Med Wochenschr. 2026 Feb;151(4):149-155. doi: 10.1055/a-2647-5748. Epub 2026 Feb 9.
2
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.利福昔明治疗肝性脑病患者的成本效益分析。
J Manag Care Spec Pharm. 2020 Jun;26(6):750-757. doi: 10.18553/jmcp.2020.26.6.750.
3
Comparison of efficacy of rifaximin, probiotics and L-ornithine L-aspartate in overt hepatic encephalopathy: a randomized, phase IV, lactulose controlled clinical trial.
Trials. 2025 Nov 21;26(1):534. doi: 10.1186/s13063-025-09173-2.
4
[Prevention and treatment of hepatic encephalopathy].[肝性脑病的防治]
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10):144-147. doi: 10.17116/jnevro2017117101144-147.
5
Management of hepatic encephalopathy in the hospital.医院中肝性脑病的管理。
Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8.
6
Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.目前针对肝硬化患者轻微肝性脑病的治疗方法。
World J Gastroenterol. 2021 Jun 14;27(22):3050-3063. doi: 10.3748/wjg.v27.i22.3050.
7
RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.利福昔明对肝硬化患者轻微肝性脑病(MHE)及肠道微生物群的影响:一项随机对照试验的研究方案
Trials. 2016 Feb 29;17(1):111. doi: 10.1186/s13063-016-1205-8.
8
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.演变的概念:轻微肝性脑病的负面影响和肝硬化患者预防的作用。
Clin Ther. 2013 Sep;35(9):1458-73. doi: 10.1016/j.clinthera.2013.07.421. Epub 2013 Aug 22.
9
Management of hepatic encephalopathy in Germany: a survey among physicians.德国肝性脑病的管理:一项针对医生的调查
Z Gastroenterol. 2020 Jan;58(1):49-56. doi: 10.1055/a-1010-6974. Epub 2020 Jan 13.
10
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.L-鸟氨酸L-天冬氨酸用于预防和治疗肝硬化患者的肝性脑病。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD012410. doi: 10.1002/14651858.CD012410.pub2.